These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26381422)

  • 1. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
    Koeth LM; DiFranco-Fisher JM; McCurdy S
    J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
    Jones RN; Sader HS; Flamm RK
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.
    Rennie RP; Koeth L; Jones RN; Fritsche TR; Knapp CC; Killian SB; Goldstein BP
    J Clin Microbiol; 2007 Oct; 45(10):3151-4. PubMed ID: 17670919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.
    Jones RN; Farrell DJ; Flamm RK; Sader HS; Dunne MW; Mendes RE
    Diagn Microbiol Infect Dis; 2015 May; 82(1):73-7. PubMed ID: 25724854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of two commercial broth microdilution systems for dalbavancin susceptibility testing of methicillin-resistant Staphylococcus aureus and other resistant Gram-positive cocci.
    Baccani I; Antonelli A; Cuffari S; Ferretti C; Giani T; Rossolini GM
    Clin Microbiol Infect; 2024 Jul; 30(7):951.e1-951.e4. PubMed ID: 38492739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
    Sader HS; Mendes RE; Pfaller MA; Flamm RK
    J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].
    Cercenado E
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():9-14. PubMed ID: 28129822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
    Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.